Skip to Content

Privigen Dosage

Generic name: Human Immunoglobulin G 5g in 50mL
Dosage form: injection

Medically reviewed on February 16, 2018.

Preparation and Handling

  • Privigen is a clear or slightly opalescent, colorless to pale yellow solution. Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the solution is cloudy, turbid, or if it contains particulate matter.
  • Do not freeze. Do not use if Privigen has been frozen.
  • Privigen should be at room temperature (up to 25ºC [77ºF]) at the time of administration.
  • Do not use Privigen beyond the expiration date on the product label.
  • The Privigen vial is for single-use only. Promptly use any vial that has been entered. Privigen contains no preservative. Discard partially used vials or unused product in accordance with local requirements.
  • Infuse Privigen using a separate infusion line. Prior to use, the infusion line may be flushed with Dextrose Injection, USP (D5W) or 0.9% Sodium Chloride for Injection, USP.
  • Do not mix Privigen with other IGIV products or other intravenous medications. However, Privigen may be diluted with Dextrose Injection, USP (D5W).
  • An infusion pump may be used to control the rate of administration.
  • If large doses of Privigen are to be administered, several vials may be pooled using aseptic technique. Begin infusion within 8 hours of pooling.


Treatment of Primary Humoral Immunodeficiency

As there are significant differences in the half-life of IgG among patients with PI, the frequency and amount of immunoglobulin therapy may vary from patient to patient. The proper amount can be determined by monitoring clinical response.

The recommended dose of Privigen for patients with PI is 200 to 800 mg/kg (2 to 8 mL/kg), administered every 3 to 4 weeks. If a patient misses a dose, administer the missed dose as soon as possible, and then resume scheduled treatments every 3 or 4 weeks, as applicable.

Adjust the dosage over time to achieve the desired serum IgG trough levels and clinical responses. No randomized, controlled trial data are available to determine an optimal trough level in patients receiving immune globulin therapy.

Treatment of Chronic Immune Thrombocytopenic Purpura

The recommended dose of Privigen for patients with chronic ITP is 1 g/kg (10 mL/kg) administered daily for 2 consecutive days, resulting in a total dosage of 2 g/kg.

The high-dose regimen (2 g/kg divided over 2 days) is not recommended for individuals with expanded fluid volumes or where fluid volume may be a concern (see Warnings and Precautions [5.8]).


Privigen is for intravenous administration only.

Monitor the patient's vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.

Ensure that patients with pre-existing renal insufficiency are not volume depleted. For patients judged to be at risk for renal dysfunction or thrombotic events, administer Privigen at the minimum infusion rate practicable, and discontinue Privigen administration if renal function deteriorates (see Boxed Warning, Warnings and Precautions [5.2, 5.4]).

Table 1 provides the recommended infusion rates for Privigen.

Table 1: Recommended Infusion Rates for Privigen
Indication Dose Initial infusion rate Maintenance infusion rate
(if tolerated)
PI 200-800 mg/kg (2-8 mL/kg) every 3-4 weeks 0.5 mg/kg/min
(0.005 mL/kg/min)
Increase to
8 mg/kg/min (0.08 mL/kg/min)
ITP 1 g/kg (10 mL/kg) for 2 consecutive days 0.5 mg/kg/min
(0.005 mL/kg/min)
Increase to
4 mg/kg/min (0.04 mL/kg/min)

The following patients may be at risk of developing inflammatory reactions on rapid infusion of Privigen (greater than 4 mg/kg/min [0.04 mL/kg/min]): 1) those who have never received Privigen or another IgG product or who have not received it within the past 8 weeks, and 2) those who are switching from another IgG product. These patients should be started at a slow rate of infusion (e.g., 0.5 mg/kg/min [0.005 mL/kg/min] or less) and gradually advanced to the maximum rate as tolerated.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.